research Provenge is Talk of GU Malignancies Congress
This article discusses the approval and perceived potential of Provenge, a new prostate cancer vaccine, highlighting its capability to extend survival in certain patients while also noting ongoing debates about its cost and mechanisms; it reports no new clinical results.
